Clinical Trial

Trial Protocol ID USOR 23235: 1L NSCLC Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

Trial Description

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

MOA: EIK1001 is a Toll-like receptor (TLR)7/8 dual agonist.

Key Eligibility Criteria:

Histologically or cytologically confirmed Stage 4 squamous or nonsquamous NSCLC and be considered for standard therapy with pembrolizumab and chemotherapy
Patient must have confirmation that mutation-directed therapy is not indicated
Patients that received prior systemic treatment for advanced/metastatic NSCLC are excluded
Patients that received radiation therapy to the lung that is > 30 Gy within 6 months of the first dose of study drug administration excluded